in vivo News and Research

RSS

Dual targeting strategy suppresses pancreatic cancer cell growth

A new research paper was published in Volume 13 of Oncoscience on January 28, 2026, titled "Dual targeting of oncogenic microtubules and mitochondria in PDAC."

10 Feb 2026

4D-printed vascular stents expand naturally at body temperature

Cardiovascular diseases constitute a major global health concern. Various complications that affect normal blood flow in arteries and veins, such as stroke, blood clot formation in veins, blood vessel rupture, and coronary artery disease, often require vascular treatments.

6 Feb 2026

Needle-thin brain implant enables recording and targeted drug delivery

A new type of brain implant may have implications for both brain research and future treatments of neurological diseases such as epilepsy.

6 Feb 2026

11th Innate Killer Summit returns to San Diego, showcasing clinical data that signals renewed momentum in NK cell therapy

The 11th Innate Killer Summit returns, bringing together global leaders advancing natural killer (NK) cell–based immunotherapies.

From Hanson Wade Group - 11th Innate Killer Summit 6 Feb 2026

SynGenSys introduces Liver.SET synthetic promoter library for liver-specific gene expression for in vivo gene therapies

SynGenSys, a biotechnology company designing synthetic gene promoter systems to address critical bottlenecks in biopharma manufacturing and enhance cell and gene therapy development, today announced the launch of its Liver.SET™ library of liver-specific synthetic promoters.

5 Feb 2026

Small molecule targets glioblastoma oncogene in preclinical studies

UVA Comprehensive Cancer Center scientists have identified a molecule that blocks the gene responsible for glioblastoma, raising hopes that the molecule could become a much-needed new treatment for the deadliest brain cancer.

4 Feb 2026

Integrated Monte Carlo and deep learning improve radiotherapy QA

Led by Professor Fu Jin, the study addresses a critical challenge in radiation therapy: balancing the computational speed and accuracy of EPID-based dose verification.

31 Jan 2026

Eosinophils suppress tumor growth and recurrence in chordoma

Chordoma is a rare tumor characterized by poor prognosis, limited therapeutic options, and a high rate of recurrence. Despite advances in oncology, effective treatments for chordoma remain limited.

31 Jan 2026

Revolutionizing 3D cell culture with simplified digital microfluidic technology

Most cells in the human body exist in complex three-dimensional environments, yet they are still commonly studied on flat plastic dishes.

30 Jan 2026

Aptamer-based wearables revolutionize continuous health tracking

Continuous monitoring of biomarkers is essential for early disease detection, treatment evaluation, and personalized health management, yet most clinical tests rely on invasive, single-point blood sampling. Recent advances in aptamer-based wearable electrochemical sensors offer a promising alternative by enabling real-time, continuous tracking of physiological signals directly in or on the body.

30 Jan 2026

Scientists offer new insight into how common parasite T. gondii causes disease

A University of California, Riverside team of scientists has found that Toxoplasma gondii, a common parasite affecting up to one-third of the global population, is far more complex than previously believed.

27 Jan 2026

New contact lens technology offers high-sensitivity, real-time intraocular pressure monitoring

Glaucoma is a leading cause of blindness among people who are unable to monitor and manage their intraocular pressure (IOP) daily. The current tools for IOP measurement are not portable, convenient, easily accessible, or capable of continuous (24/7) monitoring.

27 Jan 2026

Targeted Fab fragments dismantle the allergy trigger

Allergic diseases represent a major global health burden, placing significant strain on healthcare systems worldwide. Severe conditions such as anaphylaxis, asthma, food allergy, and allergic rhinitis are driven by immunoglobulin E (IgE), an antibody that binds to immune cells, including mast cells and basophils.

27 Jan 2026

KAIST proposes novel strategy for multifactorial Alzheimer's treatment

Conventional treatments of Alzheimer's disease, one of the most common forms of dementia, have been largely focused on targeting individual pathological features.

27 Jan 2026

Tiny plastic particles may interfere with brain processes implicated in Parkinson’s disease

Micro- and nanoplastics are increasingly detected in human tissues, including the brain, and experimental evidence suggests they can interact with biological pathways central to Parkinson’s disease pathology. This review synthesises mechanistic data indicating that plastic particles may influence protein aggregation, neuroinflammation, mitochondrial dysfunction, and the gut–brain axis, while emphasising the need for prospective human studies.

26 Jan 2026

More iron, less damage: why chronic lung infections persist

Research shows that iron-rich conditions boost Pseudomonas aeruginosa growth and biofilm formation, yet reduce virulence, complicating chronic lung infections.

26 Jan 2026

Dual-responsive nanodelivery system enhances immunotherapy efficacy in metastatic bladder cancer

Metastatic urothelial carcinoma has a poor prognosis: ~50% of muscle-invasive bladder cancer progresses to metastasis, and the 5-year survival for advanced/metastatic disease is <10%.

24 Jan 2026

Sperm RNA aging shift that may explain paternal age effects

Study reveals an 'aging cliff' in sperm RNA, linking age-related changes to early development and highlighting risks associated with advanced paternal age.

22 Jan 2026

Research suggests bamboo-based foods could support metabolic health

This systematic review synthesizes human, in vitro, and food-processing studies on bamboo consumption, finding limited but suggestive evidence for metabolic, digestive, and antioxidant benefits when products are properly prepared. It also highlights safety considerations, including potential goitrogenic effects from inadequately processed shoots, and calls for higher-quality human trials.

18 Jan 2026